DM Clinical Research is celebrating its 20th anniversary, marking two decades of expanding access to clinical trials and helping accelerate the development of innovative therapies for patients across the United States. Founded in 2006 with a vision to make clinical research more accessible and patient-centered, DM Clinical has grown into one of the nation's leading integrated clinical research networks. Over the past 20 years, the organization expanded its national footprint, therapeutic expertise, and research capabilities while remaining focused on accelerating access to innovative therapies.
"Reaching 20 years is incredibly meaningful to me. When I think about DM Clinical Research, I think first about the people, the employees who have poured their talent and heart into this organization, and the patients who have trusted us to be part of their healthcare journey," said Mohammad Millwala, Founder and CEO of DM Clinical Research. "We've experienced so much growth and change over the past two decades, but what has never changed is our commitment to our patients and to doing meaningful work that makes a difference. I'm incredibly proud of what we've built together, and I'm even more excited about what we can accomplish in the next 20 years."
Today, DM Clinical Research operates a growing network of more than 35 research sites, providing access to a patient population of 1.97 million individuals across 32 therapeutic areas. Over the past 20 years, DM Clinical Research has enrolled more than 35,000 patients in clinical trials, helping advance the development of safe, life-changing therapies for patients and communities around the world. This milestone underscores the company's critical role in bridging the gap between scientific discovery and patient care, particularly in underserved communities where access to cutting-edge treatments is often limited.
The importance of this anniversary extends beyond the company's growth. By expanding its presence in underserved areas, DM Clinical is addressing a long-standing issue in clinical research: the lack of diversity among trial participants. This focus not only improves health equity but also ensures that new therapies are effective across different populations. The company's integrated operating model, which combines local physician relationships with centralized infrastructure, has been key to its success in delivering quality, speed, and consistent execution for sponsors and contract research organizations (CROs).
DM Clinical's commitment to excellence has been recognized through numerous industry honors, including the SPRIA Award for vaccine enrollment, the Excellence in Patient Centricity Award, ViE's Best Clinical Trial Network Award, and the SCRS Site Spark Award. In 2025, CEO Mohammad Millwala was also honored with the SCRS Christine K. Pierre Site Impact Award, recognizing his leadership in advancing clinical research. These accolades reflect the company's dedication to patient-centric practices and operational efficiency, which are critical for the timely development of new treatments.
As DM Clinical enters its third decade, the company plans continued expansion into new communities, broader therapeutic expertise, and increased investment in innovative technologies. This forward-looking approach is essential in an era where the clinical trial landscape is rapidly evolving, with increased use of decentralized trials and digital health tools. By embracing these changes, DM Clinical aims to make participation in clinical trials more convenient and accessible, potentially accelerating the delivery of new therapies to patients who need them most.
The company's 20th anniversary theme, "Champions of Clinical Research: 20 Years of Impact," reflects the teamwork, innovation, and dedication that have fueled its growth. Guided by core values—Think Forward, Find a Way, Create Impact, Own It, and Win Together—DM Clinical continues to invest in its people and expand access to research. As Millwala noted, "The next chapter for DM Clinical is about expanding access to research, embracing new technologies, and ensuring more patients have the opportunity to participate in clinical trials that can change lives." This vision is not only a testament to the company's past achievements but also a roadmap for its future contributions to medical innovation.
